A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 57, Issue 1, 2016, Pages 216-218

  Hainsworth, John D ^a,b   Arrowsmith, Edward R ^a,b   McCleod, Michael ^a,c   Hsi, Eric D ^d   Hamid, Oday ^e   Shi, Peipei ^e   Lin, Boris K ^e   Fayad, Luis E ^f  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Florida Cancer Specialists   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZASTAURIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ASTHENIA; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; DRUG FATALITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INFECTION; INTERMEDIATE RISK PATIENT; LARGE CELL LYMPHOMA; LETTER; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; CLINICAL TRIAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MORTALITY; PATHOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; INDOLES; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 84954376768     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1045898     Document Type: Letter

References (13)

1. F riedberg J W, F isher R I. D iff use large B-cell lymphoma. Hematol Oncol Clin North Am 2008; 22: 941-952.
2. Mey U, Hitz F, Lohri A, et al. Diagnosis and treatment of diff use large B-cell lymphoma. Swiss Med Wkly 2012; 142: w13511.
3. Coiffi er B, Lepage E, Briè re J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diff use large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
4. Coiffi er B, Tabacof J, Shen Z-X, et al. Aggressive non-Hodgkin ' s lymphoma-long-term survival for all patients? Hematology Meeting Reports 2007; 1: 27-41.
5. King LB, Norvell A, Monroe JG. Antigen receptor-induced signal transduction imbalances associated with the negative selection of immature B cells. J Immunol 1999; 162: 2655-2662.
6. Shipp MA, Ross KN, Tamayo P, et al. Diff use large B-cell lymphoma outcome prediction by gene-expression profi ling and supervised machine learning. Nat Med 2002; 8: 68-74.
7. Dutton A, Reynolds GM, Dawson CW, et al. Constitutive activation of phosphatidyl ? inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 2005; 205: 498-506.
8. Chaiwatanatorn K, Stamaratis G, Opeskin K, et al. Protein kinase C-beta II expression in diff use large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab. Leuk Lymphoma 2009; 50: 1666-1675.
9. Riihijarvi S, Koivula S, Nyman H, et al. Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diff use large B-cell lymphoma patients. Mod Pathol 2010; 23: 686-693.
10. Graff J R, M cNulty A M, H anna K R, et al. Th e protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615. HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65: 7462-7469.
11. Cheson BD, Horning SJ, Coiffi er B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin ' s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
12. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diff use large B-cell lymphoma. J Clin Oncol 2007; 25: 1741-1746.
13. Crump M, Lepp ä S, Fayad LE, Lee J-J, et al. A phase III study of enzastaurin in patients with high-risk diff use large B cell lymphoma following response to primary treatment: the Prelude trial. Blood 2013; 122: 371 (Abstract).